Three independent discounted-cash-flow-style models value PTC Therapeutics, Inc. every trading day. 0 of 3 currently price PTCT above its market price.
| Free Cash Flow model | $-1,091.32 |
| Excess Profit model | $-861.80 |
| Residual Earnings model | $-1.06 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +35.5% |
| Net debt / EBITDA | 2.5× |
| Gross margin | +97.3% |
| Revenue CAGR | +47.6% |
| Cash conversion | 1.0× |
| Dividend yield | — |
| Buyback yield | -6.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open PTCT in StockKitty